Keywords: intuniv, cuts, symptoms, adhd, children, uk-based, specialty
Intuniv cuts symptoms in ADHD children
Article | 26 May 2009
UK-based specialty pharmaceutical company Shire has reported that its clinical study of Intuniv (guanfacine) extended-release selective alpha-2A-agonist met its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
